Duchenne UK is pleased to share news from Santhera Pharmaceuticals regarding the progress of Raxone. MHRA has granted Raxone a positive scientific opinion through the EAMS.Read more
Duchenne UK is pleased to announce the launch of its ‘Innovate’ Grant Call, and invites proposals for funding projects up to £1million, dedicated to finding new treatments for Duchenne muscular dystrophy (DMD).Read more
Santhera announces an updated timeline for the ongoing assessment by the Committee for Medicinal Products for Human Use of its application for Raxone®Read more
Duchenne UK is pleased to announce that Naomi Litchfield (nee Antcliff) is joining as Director of Research and Patient Engagement. Naomi will be known to families who have taken part in research at Great Ormond Street Hospital.Read more
Duchenne UK is delighted to share this announcement from Solidbio about their investigational micro-dystrophin gene therapy, which is planned to go into clinical trials later this year.Read more
Our co-founder Alex Johnson spoke about patient perspective on outcome measures at the International Clinical Trials Methodology Conference. This article contains the abstract.Read more
As part of our community engagement work Duchenne UK launches patient survey to better understand the hopes and expectations of patients and caregivers who are considering taking part in clinical trials. This will be the first survey in our series.Read more
Duchenne UK is co-funding a study into the use of elastase inhibitors to treat the symptoms of Duchenne Muscular Dystrophy (DMD) in partnership with Joining Jack and Charley's Fund.Read more
TACT is a unique multi-disciplinary international group of academic, industry drug development experts and representatives of patient foundations and institutional governmental scientific research centers.Read more
Alex and Emily went to Newcastle to see the newly refurbished Clinical Research Facility.Read more
Duchenne UK is hosting its first Duchenne Information Day in the North West. We’re hosting it in collaboration with Alder Hey Children's Hospital, the National Institute for Health Research Alder Hey Clinical Research Facility, the DMD Hub and TREAT-NMD.Read more
Duchenne UK will fund the development of digital technology to develop and evaluate new approaches to measuring efficacy and safety in clinical trialsRead more